December 19, 2024

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)
Contact: Richard Kincaid, Executive Officer CFO
(TEL: 03-4590-8009)

Announcement of Changes in Management

HEALIOS K.K. ("Healios") announces the following changes in management.

1. Changes of Executive Officers (January 1, 2025)

Name	New position	Current position
Masanori Sawada	Executive Vice President CMO (Chief Medical Officer) in charge of development management, business development, medical material and equipment, administration	Executive Vice President CMO (Chief Medical Officer) in charge of development & human resources and general affairs
Hironobu Kimura	Executive Officer in charge of research and manufacturing, Head of Kobe Research Institute	Head of the Research Division

Reason for the appointment of the new Executive Officer
After completing his doctorate, Dr. Kimura worked in academia, and from April 2007 he was an assistant professor at the Institute for Protein Research at Osaka University. He joined Healios on April 1, 2016, and after being appointed as the head of the Research Division on September 1, 2018, he has been leading the Research Division under the direction of the former CSO Dr. Tamura for a long time and has achieved many research results, so he is suitable as an executive officer

2. Resignation as an Executive Officer (December 31, 2024)

Koichi Tamura

Executive Officer CSO (Chief Scientific Officer) in charge of research and manufacturing, Head of Kobe Research Institute

As an advisor, Dr. Tamura will continue to support Healios' research and manufacturing operations as well as our business promotion.